Replimune (REPL) said Sunday it is now evaluating RP2 in combination with nivolumab for metastatic uveal melanoma in a phase 2/3 trial based on results from the phase 1 trial.

The company said in its phase 1 first-in-human trial, RP2 monotherapy achieved an objective response rate of 19% in patients with advanced solid tumors. RP2 in combination with nivolumab had an objective response rate of 19.1%, it said.

In uveal melanoma, the pooled objective response rate, which included RP2 in combination with nivolumab and RP2 monotherapy, was 33.3%, it said.

The phase 1 first-in-human trial had enrolled 85 heavily pretreated patients with advanced solid tumors, including uveal melanoma, colorectal cancer, head and neck cancers, pancreatic cancer, cutaneous melanoma, and sarcoma, the company said.

Shares of the company were up over 13% in Monday's premarket activity.

Price: 9.90, Change: +1.21, Percent Change: +13.92